Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1/CTLA4 Antibody and Neoadjuvant Short-course Radiotherapy in Early-stage Low Rectal Cancer
NCT07837362Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in rectal cancer, sponsored by Fudan University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07837362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07837362.